2708 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

hours per 

response 

Annual 

burden 

hours 

ANA Project Outcome Assessment Survey .................................................................. 85 1 6 510 

Authority: 42 U.S.C. 2992. 

Mary C. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2025–00490 Filed 1–10–25; 8:45 am] 

BILLING CODE 4184– 34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Oncology 1-Basic 

Translational Integrated Review Group; 

Cancer Cell Biology Study Section 

Date: February 6–7, 2025. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alyssa Diane Gregory, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, alyssa.gregory@nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Child Psychopathology and 

Developmental Disabilities Study Section. 

Date: February 10–12, 2025. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Karen Elizabeth Seymour, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1000–E, 

Bethesda, MD 20892, (301) 443–9485, 

karen.seymour@nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; 

Maximizing Investigators’ Research Award— 

F Study Section. 

Date: February 10–11, 2025. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience, Integrated Review 

Group; Brain Injury and Neurovascular 

Pathologies Study Section. 

Date: February 10–11, 2025. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alexander Yakovlev, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5206, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1254, yakovleva@csr.nih.gov. 

Name of Committee: Interdisciplinary 

Molecular Sciences and Training Integrated 

Review Group; Cellular and Molecular 

Technologies Study Section. 

Date: February 11–12, 2025. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Tatiana V. Cohen, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5213, 

Bethesda, MD 20892, 301–455–2364, 

tatiana.cohen@nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Macromolecular Structure 

and Function B Study Section. 

Date: February 11–12, 2025. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alexei A. Yeliseev, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 443–0552, yeliseeva@

mail.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Pathogenic Eukaryotes Study Section. 

Date: February 11–12, 2025. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Jennifer Chien Villa, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–496–5436, jennifer.villa@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2025–00458 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Statement of Delegation of Authority 

Notice is hereby given that I have 

delegated to the Director, National 

Institutes of Health (NIH), the authority 

vested in the Secretary of Health and 

Human Services under the Dr. 

Emmanuel Bilirakis and Honorable 

Jennifer Wexton National Plan to End 

Parkinson’s Act (Pub. L. 118–66) (Act). 

The Act amends Title III of the Public 

Health Service Act by adding section 

399OO, 42 U.S.C. 280n. The Act directs 

the Secretary to carry out a national 

project to prevent, diagnose, treat, and 

cure Parkinson’s, to be known as the 

National Parkinson’s Project, including 


ddrumheller on DSK120RN23PROD with NOTICES1

I I 
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 2709 

a requirement to establish and maintain 

an Advisory Council on Parkinson’s 

Research, Care, and Services and to 

create, maintain, and periodically 

update a national plan to prevent, 

diagnose, treat, and cure Parkinson’s, 

ameliorate symptoms, and slow or stop 

progression. 

This authority may be redelegated. 

Exercise of this authority shall be in 

accordance with established policies, 

procedures, guidelines, and regulations 

as prescribed by the Secretary. The 

Secretary retains the authority to submit 

reports to Congress, promulgate 

regulations, and appoint members to the 

Advisory Council on Parkinson’s 

Research, Care, and Services. This 

Advisory Council will be co-chaired by 

the National Institutes of Health and the 

Office of the Assistant Secretary for 

Health. This delegation is effective 

immediately. 

Dated: January 6, 2025. 

Xavier Becerra, 

Secretary. 

[FR Doc. 2025–00432 Filed 1–7–25; 11:15 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2025–1 Phase I: Software or Web Services to 

Assess Quality and Reproducibility of Data 

and Information about Therapeutics and 

Vaccines (Topic 147). 

Date: February 5, 2025. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Rockville, MD 

20892 (Video Assisted Meeting). 

Contact Person: Sandip Bhattacharyya, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, National Institute of Allergy 

and Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, MSC–9823, 

Rockville, MD 20892, sandip.bhattacharyya@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2025–00457 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS– 

2025–1 Phase I and II: Development of 

Medical Interventions for Treating NonTuberculosis Mycobacterial (NTM) Infections 

(Topic 144). 

Date: February 3, 2025. 

Time: 1:00 p.m. to 3:00 p.m. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Rockville, MD 

20892 (Video Assisted Meeting). 

Agenda: To review and evaluate contract 

proposals. 

Contact Person: Mario Cerritelli, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, MSC–9823, Rockville, MD 

20892, 240–669–5199, cerritem@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2025–00462 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders C Study Section. 

Date: February 3–4, 2025. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Meeting Format: Virtual Meeting. 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–496– 

9223, Ana.Olariu@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 6, 2025. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2025–00470 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 


ddrumheller on DSK120RN23PROD with NOTICES1